CN114588201B

CN114588201B - Preparation method of cistanche extract and anti-alcohol liver-protecting product containing cistanche extract

Info

Publication number: CN114588201B
Application number: CN202210332114.0A
Authority: CN
Inventors: 王强; 常森林
Original assignee: Beijing Zhongke Joinyou Biotechnology Co ltd
Current assignee: Beijing Zhongke Joinyou Biotechnology Co ltd
Priority date: 2022-03-30
Filing date: 2022-03-30
Publication date: 2024-01-02
Anticipated expiration: 2042-03-30
Also published as: CN114588201A

Abstract

The invention relates to a preparation method of cistanche extract and an anti-alcohol liver-protecting product containing the cistanche extract, and the preparation method comprises the following steps: (1) Mixing cistanche deserticola and acid liquor to obtain pretreated cistanche deserticola; (2) Mixing the pretreated cistanche salsa, the solvent and the cyclodextrin auxiliary agent obtained in the step (1), and then carrying out solid-liquid separation to obtain an extracting solution; (3) And (3) concentrating and drying the extract obtained in the step (2) in sequence to obtain the cistanche extract. The product for dispelling the effects of alcohol and protecting liver comprises cistanche extract, functional components and auxiliary materials. The preparation method of the cistanche extract provided by the invention can obviously improve the extraction rate of phenylethanoid glycosides in the cistanche extract, and the anti-alcoholic liver-protecting product provided by the invention can promote the rapid absorption and decomposition of alcohol in vivo, has better effects on rapidly dispelling alcohol and preventing hangover for alcohol ingestion people, and has better liver-protecting effect.

Description

Preparation method of cistanche extract and anti-alcohol liver-protecting product containing cistanche extract

Technical Field

The invention relates to the field of traditional Chinese medicine component extraction, in particular to a preparation method of cistanche extract and an anti-alcohol liver-protecting product containing the cistanche extract.

Background

The liver is an important organ for metabolism of human body, and has the important functions of expelling toxin, removing toxicity, secreting bile and the like. This is also true of alcohol, which is about 90% of the alcohol that is consumed by the human body is metabolized by the liver. When the intake of alcohol in human body is greatly beyond the bearable range, the long-term high-load operation of liver causes the metabolism of stem cells to be disturbed, further causes the damage of liver and the decline of liver function, and brings great crisis to various body functions of human body.

In the society of economic rapid development nowadays, people habitually drink wine in families or various gathering places, and wine even becomes a common life drink for people. However, if alcohol is not metabolized in the body in time and discharged out of the body after excessive drinking, the alcohol is liable to cause injury to the body. Drunk people seriously affect the physical health and family life of people, and excessive drinking can damage the liver and even cause alcoholism.

Most of the prior anti-alcoholic drugs have certain elimination effect on symptoms after drinking, but have no good recovery effect on liver injury and liver degeneration, and excessive intake can further increase the burden of the body. Compared with medicines, the health food can not burden the human body after long-term eating, and the effective components in the health food can gradually carry out systematic adjustment and treatment on the human body in the long-term eating process.

CN101716001a discloses a beverage for alleviating hangover and protecting liver and a production method, the beverage mainly comprises: 15% of kudzuvine root, 10% of virgate wormwood herb, 10% of kudzuvine flower, 10% of fructus momordicae, 10% of tamarind, 10% of fructus aurantii, 10% of semen hoveniae, 10% of liquorice, 15% of dried orange peel, 5% of pectin and 3% of peppermint, and has the effects of protecting liver, promoting urination and the like.

CN107007786a discloses a pharmaceutical composition with the effects of dispelling effects of alcohol, protecting kidney and protecting liver, which comprises hovenia dulcis thunb, antrodia camphorata, seed of cao guo, kudzu vine flower, yam and the like, and has the effects of dispelling effects of alcohol, protecting kidney and protecting liver.

At present, although there are anti-alcoholic products compounded by traditional Chinese medicines or other plants in the market, the functional components are not clear and the content is low, the functional components contained in the Chinese herbal medicines are not easy to extract, and the anti-alcoholic and liver-protecting effects are very limited.

Therefore, an extraction method with high extraction amount of functional components is developed, and the prepared traditional Chinese medicine composition with good protection and auxiliary treatment effects on alcoholic liver injury has important practical significance.

Disclosure of Invention

Compared with the prior art, the preparation method provided by the invention can obviously improve the content of phenylethanoid glycosides in the extract, and the anti-alcoholic liver protection product provided by the invention has the protection function and the auxiliary treatment effect on alcoholic liver injury and has good pharmacological effect.

In order to achieve the aim of the invention, the invention adopts the following technical scheme:

in a first aspect, the present invention provides a method for preparing cistanche extract, comprising the steps of:

(1) Mixing cistanche deserticola and acid liquor to obtain pretreated cistanche deserticola;

(2) Mixing the pretreated cistanche salsa, the solvent and the cyclodextrin auxiliary agent obtained in the step (1), and then carrying out solid-liquid separation to obtain an extracting solution;

(3) And (3) concentrating and drying the extract obtained in the step (2) in sequence to obtain the cistanche extract.

In the invention, the cistanche is pretreated by acid liquor, the acid liquor can promote the conversion of non-phenethyl alcohol glycoside substances in the cistanche into phenethyl alcohol glycoside, so that the phenethyl alcohol glycoside content in the cistanche is obviously improved, the extraction is carried out by a solvent and cyclodextrin auxiliary agents, the cyclodextrin auxiliary agents can form an embedding body with the phenethyl alcohol glycoside with poor water solubility, the extraction rate and the dissolution performance of the phenethyl alcohol glycoside in the cistanche are obviously improved, and the concentration and the drying are sequentially carried out, so that the phenethyl alcohol glycoside content and the extraction rate in the cistanche extract are further improved. Compared with the method of ethanol soaking and ultrasonic extraction, the preparation method of the invention can greatly improve the extraction rate of phenylethanoid glycosides in cistanche and is more beneficial to the development of subsequent products through a series of combined operations of acid liquor pretreatment, mixed extraction of solvent and cyclodextrin auxiliary agent, concentration, drying and the like.

In the invention, the cistanche extract is a crude extract and can be purified again.

Preferably, the acid solution of step (1) comprises any one or a combination of at least two of citric acid, ascorbic acid, hydrochloric acid, phytic acid, L-cysteine, potassium sorbate, sulfuric acid, phosphoric acid, oxalic acid or glycine, wherein typical but non-limiting combinations include combinations of citric acid and ascorbic acid, combinations of ascorbic acid and hydrochloric acid, combinations of hydrochloric acid and phytic acid or combinations of potassium sorbate, sulfuric acid and phosphoric acid.

Preferably, the acid solution is 0.01-5% by mass, for example, 0.01%, 0.02%, 0.04%, 0.06%, 0.08%, 0.1%, 0.2%, 0.5%, 0.8%, 1%, 1.2%, 1.5%, 1.8%, 2%, 2.2%, 2.5%, 2.8%, 3%, 3.2%, 3.5%, 3.8%, 4%, 4.2%, 4.5%, 4.8% or 5%, but not limited to the recited values, and other non-recited values in the numerical range are equally applicable.

The invention preferably controls the mass percentage of the acid liquor within a specific range, so that on one hand, the conversion of non-phenethyl alcohol glycoside substances in cistanche to phenethyl alcohol glycoside substances can be avoided, and on the other hand, the cost increase caused by the too high acid liquor concentration can be avoided.

Preferably, the mixing of step (1) comprises soaking.

Preferably, the soaking time is 0.25-24h, for example, 0.25h, 0.5h, 0.75h, 1h, 2h, 3h, 4h, 5h, 6h, 7h, 8h, 9h, 10h, 11h, 12h, 13h, 14h, 15h, 16h, 17h, 18h, 19h, 20h, 21h, 22h, 23h or 24h, but not limited to the recited values, and other non-recited values within the range of values are equally applicable.

The invention preferably controls the soaking time in a specific range, so that the extraction rate of phenylethanoid glycosides can be higher.

Preferably, the soaking temperature is 5-100deg.C, for example, 5 ℃, 6 ℃, 7 ℃, 8 ℃, 9 ℃, 10 ℃, 20 ℃, 25 ℃, 30 ℃, 35 ℃, 40 ℃, 45 ℃, 50 ℃, 55 ℃, 60 ℃, 65 ℃, 70 ℃, 75 ℃, 80 ℃, 85 ℃, 90 ℃, 95 ℃ or 100 ℃, but not limited to the recited values, other non-recited values within the numerical range are equally applicable.

Preferably, the cistanche includes cistanche deserticola and/or cistanche tubulosa, preferably cistanche deserticola.

Preferably, the cistanche includes fresh cistanche and/or dry cistanche, preferably fresh cistanche.

Preferably, slicing is performed before the cistanche deserticola is mixed.

Preferably, the thickness of the slice is 1-10mm, and may be, for example, 1mm, 2mm, 3mm, 4mm, 5mm, 6mm, 7mm, 8mm, 9mm or 10mm, but is not limited to the recited values, and other non-recited values within the range of values are equally applicable.

Preferably, the solvent of step (2) comprises an ethanol solution.

Preferably, the volume concentration of the ethanol after mixing in the step (2) is 20-80%, for example, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75% or 80%, but not limited to the recited values, and other non-recited values in the numerical range are equally applicable.

Preferably, the solid-to-liquid ratio of the pretreated cistanche salsa to the ethanol solution is 1 (10-50) g/L, for example, 1:10g/L, 1:12g/L, 1:15g/L, 1:18g/L, 1:20g/L, 1:22g/L, 1:25g/L, 1:28g/L, 1:30g/L, 1:32g/L, 1:35g/L, 1:38g/L, 1:40g/L, 1:42g/L, 1:45g/L, 1:48g/L or 1:50g/L, but the solid-to-liquid ratio is not limited to the recited values, and other non-recited values in the numerical range are equally applicable.

Preferably, the cyclodextrin-based adjuvant comprises any one or a combination of at least two of α -cyclodextrin, β -cyclodextrin, γ -cyclodextrin or hydroxypropyl- β -cyclodextrin, wherein typical but non-limiting combinations include a combination of α -cyclodextrin and β -cyclodextrin, a combination of β -cyclodextrin and γ -cyclodextrin or a combination of β -cyclodextrin, γ -cyclodextrin and hydroxypropyl- β -cyclodextrin.

Preferably, the mass of the cyclodextrin auxiliary agent is 10-80% of the solid content of the pretreated cistanche, for example, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75% or 80%, but not limited to the recited values, and other non-recited values in the numerical range are equally applicable.

The invention preferably controls the mass of the cyclodextrin auxiliary agent to be in a specific range in percentage of the solid content of the pretreated cistanche, can ensure higher extraction rate, simultaneously avoids marginal effect caused by excessive addition of the cyclodextrin auxiliary agent, and reduces cost.

Preferably, the mixing in step (2) is followed by extraction.

Preferably, the temperature of the extraction is 50-80 ℃, for example, 50 ℃, 52 ℃, 55 ℃, 58 ℃, 60 ℃, 62 ℃, 65 ℃, 68 ℃, 70 ℃, 72 ℃, 75 ℃, 78 ℃ or 80 ℃, but not limited to the recited values, other non-recited values within the numerical range are equally applicable.

The invention preferably controls the extraction temperature in a specific range, so that the extraction amount and extraction rate of phenylethanoid glycosides are higher.

Preferably, the extraction time is 0.25-4h, for example, 0.25h, 0.5h, 0.75h, 1h, 1.2h, 1.5h, 1.8h, 2h, 2.2h, 2.5h, 2.8h, 3h, 3.2h, 3.5h, 3.8h or 4h, but not limited to the recited values, and other non-recited values within the range of values are equally applicable.

The invention preferably controls the extraction time in a specific range, so that the extraction amount and extraction rate of phenylethanoid glycosides can be higher.

Preferably, the concentrating of step (3) comprises vacuum concentrating under reduced pressure.

Preferably, the temperature of the concentration is 60-80 ℃, for example, 60 ℃, 62 ℃, 65 ℃, 68 ℃, 70 ℃, 72 ℃, 75 ℃, 78 ℃ or 80 ℃, but the concentration is not limited to the recited values, and other non-recited values within the range of values are equally applicable.

Preferably, the concentration is terminated by an extraction liquid having a specific gravity of 1.1-1.15, for example, 1.1, 1.11, 1.12, 1.13, 1.14 or 1.15, but not limited to the recited values, and other non-recited values within the range of values are equally applicable.

Preferably, the drying comprises spray drying.

As a preferred technical solution of the first aspect of the present invention, the preparation method includes the following steps:

(1) Soaking the sliced cistanche in acid liquor for 0.25-4h at the temperature of 5-100 ℃ to obtain pretreated cistanche, wherein the acid liquor comprises any one or a combination of at least two of citric acid, ascorbic acid, hydrochloric acid, phytic acid, L-cysteine, potassium sorbate, sulfuric acid, phosphoric acid, oxalic acid or glycine, and the mass percentage of the acid liquor is 0.01-5%;

(2) Mixing the pretreated cistanche salsa obtained in the step (2), ethanol and cyclodextrin auxiliary agent, and extracting for 0.24-4 hours at 50-80 ℃ to obtain an extracting solution; the volume concentration of the ethanol after mixing is 20-80%, the solid-to-liquid ratio of the pretreated cistanche deserticola to the ethanol solution is 1 (10-50) g/L, the cyclodextrin auxiliary agent comprises any one or a combination of at least two of alpha-cyclodextrin, beta-cyclodextrin, gamma-cyclodextrin and hydroxypropyl-beta-cyclodextrin, and the mass of the cyclodextrin auxiliary agent is 10-80% of the solid content of the pretreated cistanche deserticola;

(3) Concentrating the extract obtained in the step (2) at 60-80deg.C until the specific gravity of the extract is 1.1-1.15, and drying to obtain herba cistanches extract.

In a second aspect, the invention provides an anti-hangover and liver-protecting product, which comprises the cistanche extract prepared by the preparation method of the cistanche extract in the first aspect;

the product also comprises functional components and auxiliary materials.

The product for dispelling the effects of alcohol and protecting liver is added with cistanche extract, functional components and auxiliary materials. The cistanche extract disclosed by the invention is treated by acid liquor, the non-phenylethanoid glycosides are converted into phenylethanoid glycosides, the content of phenylethanoid glycosides is effectively improved, and an embedded object is formed by cyclodextrin and phenylethanoid glycosides. In addition, cistanche has antibacterial, antiinflammatory, antiviral, antitumor, antioxidant, immunoregulatory, memory improving, liver protecting and heart strengthening effects. The anti-hangover and liver-protecting product provided by the invention is prepared from cistanche extract serving as a main functional component, and can achieve a good anti-hangover and liver-protecting effect by synergistic combination of cistanche extract, other functional components and auxiliary materials, has no side effect, and can be taken for a long time.

Preferably, the functional ingredients include kudzu root extract, licorice extract, hovenia dulcis thunb extract and poria extract.

The invention preferably controls the functional components including the kudzu root extract, the licorice extract, the hovenia dulcis thunb extract and the poria cocos extract, can play a synergistic effect with the cistanche deserticola extract, and has better effects of dispelling the effects of alcohol and protecting the liver.

Preferably, the puerarin content is 1-20% by dry weight of the pueraria extract, for example, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19% or 20%, but not limited to the recited values, and other non-recited values within the range of values are equally applicable.

Preferably, the content of glycyrrhizin is 5% or more, for example, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19% or 20% calculated on dry weight of the licorice extract, but not limited to the recited values, and other non-recited values in the range of values are equally applicable.

Preferably, the pachyman content is not less than 10%, for example, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19% or 20%, based on the dry weight of the pachyman extract, but not limited to the recited values, and other non-recited values within the range of values are equally applicable.

Preferably, the content of hovenia dulcis thunb polysaccharide is not less than 5%, for example, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19% or 20% based on the dry weight of the hovenia dulcis thunb extract, but not limited to the recited values, other non-recited values within the range of values are equally applicable.

Preferably, the anti-hangover and liver-protecting product comprises 1-35 parts of cistanche extract, for example, 1 part, 2 parts, 4 parts, 6 parts, 8 parts, 10 parts, 12 parts, 14 parts, 16 parts, 18 parts, 20 parts, 22 parts, 24 parts, 26 parts, 28 parts, 30 parts, 32 parts, 34 parts or 35 parts, by weight, of cistanche extract, but not limited to the recited values, and other non-recited values in the range of values are equally applicable, and preferably 15-25 parts.

Preferably, the anti-hangover and liver-protecting product comprises 2-10 parts of radix puerariae extract, for example, 2 parts, 3 parts, 4 parts, 5 parts, 6 parts, 7 parts, 8 parts, 9 parts or 10 parts, by weight, but is not limited to the recited values, and other non-recited values in the range of values are equally applicable, preferably 3-6 parts.

Preferably, the anti-hangover and liver-protecting product comprises 1-10 parts of licorice extract, for example, 1 part, 2 parts, 3 parts, 4 parts, 5 parts, 6 parts, 7 parts, 8 parts, 9 parts or 10 parts, by weight, but is not limited to the recited values, and other non-recited values in the numerical range are equally applicable, preferably 2-5 parts.

Preferably, the anti-hangover and liver-protecting product comprises 2-10 parts by weight of semen hoveniae extract, for example, 2 parts, 3 parts, 4 parts, 5 parts, 6 parts, 7 parts, 8 parts, 9 parts or 10 parts, but is not limited to the recited values, and other non-recited values in the range of values are equally applicable, preferably 3-6 parts.

Preferably, the anti-hangover and liver-protecting product comprises 1-10 parts by weight of poria cocos extract, for example, 1 part, 2 parts, 3 parts, 4 parts, 5 parts, 6 parts, 7 parts, 8 parts, 9 parts or 10 parts, but is not limited to the recited values, and other non-recited values in the range of values are equally applicable, preferably 1-5 parts.

Preferably, the functional ingredient further comprises any one or a combination of at least two of astragalus extract, schisandra extract or lycium extract, wherein typical but non-limiting combinations include a combination of astragalus extract and schisandra extract or a combination of schisandra extract and lycium extract.

Preferably, the astragalus polysaccharide content is greater than or equal to 5%, such as 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19% or 20% by dry weight of the astragalus extract, but not limited to the recited values, other non-recited values within the range of values are equally applicable.

Preferably, the schisandra polysaccharide content is not less than 10%, for example, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19% or 20%, calculated on the dry weight of the schisandra extract, but not limited to the recited values, and other non-recited values in the numerical range are equally applicable.

Preferably, the content of the lycium barbarum polysaccharide is greater than or equal to 10%, such as 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19% or 20%, calculated on the dry weight of the lycium barbarum extract, but not limited to the recited values, and other non-recited values within the range of values are equally applicable.

Preferably, the anti-hangover and liver-protecting product comprises 1-10 parts of astragalus extract by weight, for example, 1 part, 2 parts, 3 parts, 4 parts, 5 parts, 6 parts, 7 parts, 8 parts, 9 parts or 10 parts of astragalus extract by weight, but is not limited to the recited values, and other non-recited values in the range of values are equally applicable.

Preferably, the anti-hangover and liver-protecting product comprises 1-10 parts of schisandra chinensis extract by weight, for example, 1 part, 2 parts, 3 parts, 4 parts, 5 parts, 6 parts, 7 parts, 8 parts, 9 parts or 10 parts, but is not limited to the recited values, and other non-recited values in the range of values are equally applicable.

Preferably, the antialcoholic liver-protecting product comprises 1-10 parts by weight of the wolfberry extract, for example, 1 part, 2 parts, 3 parts, 4 parts, 5 parts, 6 parts, 7 parts, 8 parts, 9 parts or 10 parts, but is not limited to the recited values, and other non-recited values in the numerical range are equally applicable, preferably 1-5 parts.

Preferably, the adjunct comprises any one or a combination of at least two of xylitol, dextrin, maltodextrin, magnesium stearate, microcrystalline cellulose, taurine, vitamins, sucrose, honey, citric acid or fruit powder, wherein typical but non-limiting combinations include combinations of xylitol and dextrin, combinations of dextrin and maltodextrin or combinations of maltodextrin, magnesium stearate and microcrystalline cellulose.

Preferably, the anti-hangover and liver-protecting product comprises any one of tablets, capsules, pills, solid beverages, soft sweets, effervescent tablets, chewable tablets, oral liquids or beverages.

Compared with the prior art, the invention has the following beneficial effects:

(1) The preparation method of the cistanche extract provided by the invention can obviously improve the content of the phenethyl alcohol glycoside in the cistanche extract and the dissolution property of the phenethyl alcohol glycoside, and the mass percent of the phenethyl alcohol glycoside in the obtained cistanche extract is more than or equal to 10%, wherein the mass percent of the echinacoside is more than or equal to 5%, and the extraction rate of the phenethyl alcohol glycoside is more than or equal to 11.4mg/g of raw material cistanche.

(2) The anti-hangover and liver-protecting product provided by the invention can promote the rapid absorption and decomposition of alcohol in vivo, has good effects on rapidly relieving alcohol and preventing hangover for alcohol ingestion, has good liver-protecting effect, can increase the metabolism speed of alcohol in vivo, effectively relieves symptoms such as headache, dizziness, nausea, vomiting, fever, polydipsia and the like after drunk, shortens the sobering time, and has good effect on preventing liver injury caused by alcohol metabolism.

(3) The anti-hangover and liver-protecting product provided by the invention is developed into products with different dosage forms such as tablets, capsules, pills, solid beverages, soft sweets, effervescent tablets, chewable tablets, oral liquid or beverages and the like according to different scene requirements, and meets the requirements of different crowds.

Drawings

Fig. 1 is a graph showing the results of an anti-hangover and liver-protecting product provided in application example 1 of the present invention in an anti-hangover experiment on mice;

fig. 2 is a graph showing the results of an anti-hangover experiment on mice by using the anti-hangover and liver-protecting product provided in application example 1 of the present invention;

fig. 3 is a graph showing the results of a test of a mouse post-drinking climbing with the anti-hangover and liver-protecting product according to application example 1 of the present invention.

Detailed Description

The technical scheme of the invention is further described by the following specific embodiments. It will be apparent to those skilled in the art that the examples are merely to aid in understanding the invention and are not to be construed as a specific limitation thereof.

Example 1

The embodiment provides a preparation method of cistanche deserticola extract, which comprises the following steps:

(1) Fresh cistanche deserticola is washed and cut into slices with the thickness of 5mm, and then soaked in acid liquor for 1h at room temperature to obtain pretreated cistanche deserticola, wherein the acid liquor is a mixed solution of 1% hydrochloric acid, 1% ascorbic acid, 1% citric acid, 1% phytic acid and 1% cysteine (based on mass concentration);

(2) Mixing the pretreated cistanche salsa obtained in the step (2), ethanol and alpha-cyclodextrin, and extracting for 2 hours at 80 ℃, wherein the volume concentration of the ethanol after mixing is 50%, so as to obtain an extract; the solid-to-liquid ratio of the pretreated cistanche deserticola to the ethanol solution is 1:30g/L, and the mass of the alpha-cyclodextrin is 10% of the solid content of the pretreated cistanche deserticola;

(3) Concentrating the extract obtained in the step (2) at 60 ℃ under vacuum and reduced pressure until the specific gravity of the extract is 1.15, and then performing spray drying to obtain the cistanche deserticola extract.

Example 2

(1) The cistanche deserticola dry product is washed and cut into slices with the thickness of 1mm, and is soaked in acid liquor for 0.25h at the temperature of 100 ℃ to obtain pretreated cistanche deserticola, wherein the acid liquor is a mixed solution of (by mass concentration) 2% hydrochloric acid, 1.5% ascorbic acid, 0.5% citric acid and 2% phytic acid;

(2) Mixing the pretreated cistanche salsa obtained in the step (2), ethanol and beta-cyclodextrin, and extracting for 2 hours at 50 ℃, wherein the volume concentration of the ethanol after mixing is 20%, so as to obtain an extract; the solid-to-liquid ratio of the pretreated cistanche deserticola to the ethanol solution is 1:10g/L, and the mass of the beta-cyclodextrin is 80% of the solid content of the pretreated cistanche deserticola;

(3) Concentrating the extract obtained in the step (2) at 70 ℃ under vacuum and reduced pressure until the specific gravity of the extract is 1.10, and then performing spray drying to obtain the cistanche deserticola extract.

Example 3

(1) The fresh cistanche tubulosa is washed and cut into slices with the thickness of 10mm, and then soaked in acid liquor for 24 hours at the temperature of 5 ℃ to obtain pretreated cistanche tubulosa, wherein the acid liquor is 1% hydrochloric acid (in terms of mass concentration);

(2) Mixing the pretreated cistanche salsa obtained in the step (2), ethanol and gamma-cyclodextrin, and extracting for 4 hours at 40 ℃, wherein the volume concentration of the ethanol after mixing is 60%, so as to obtain an extract; the solid-to-liquid ratio of the pretreated cistanche deserticola to the ethanol solution is 1:50g/L, and the mass of the gamma-cyclodextrin is 40% of the solid content of the pretreated cistanche deserticola;

(3) Concentrating the extract obtained in the step (2) at 80 ℃ under vacuum and reduced pressure until the specific gravity of the extract is 1.15, and then performing spray drying to obtain the cistanche deserticola extract.

Example 4

(1) Fresh cistanche deserticola is cleaned and cut into slices with the thickness of 5mm, and then soaked in acid liquor for 2 hours at room temperature to obtain pretreated cistanche deserticola, wherein the acid liquor is (in terms of mass concentration) 2% of ascorbic acid;

(2) Mixing the pretreated cistanche salsa obtained in the step (2), ethanol and hydroxypropyl-beta-cyclodextrin, and extracting for 0.24h at 50 ℃, wherein the volume concentration of the ethanol after mixing is 70%, so as to obtain an extract; the solid-to-liquid ratio of the pretreated cistanche deserticola to the ethanol solution is 1:30g/L, and the mass of the hydroxypropyl-beta-cyclodextrin is 60% of the solid content of the pretreated cistanche deserticola;

Comparative example 1

The comparative example provides a preparation method of cistanche deserticola extract, which comprises the steps of mixing dry cistanche deserticola with ethanol with the volume concentration of 20%, extracting the dry cistanche deserticola with the ethanol solution for 2 hours at 50 ℃ at the solid-to-liquid ratio of 1:10g/L to obtain an extract; concentrating the extractive solution at 70deg.C under reduced pressure until the specific gravity of the extractive solution is 1.10, and spray drying to obtain herba cistanches extract.

Comparative example 2

This comparative example provides a preparation method of cistanche extract, which is different from example 2 only in that step (1) is omitted.

Comparative example 3

This comparative example provides a preparation method of cistanche extract, which is different from example 2 only in that step (2) does not add beta-cyclodextrin.

The phenylethanoid glycosides in the cistanche extracts obtained in examples 1 to 4 and comparative examples 1 to 3 were measured by liquid chromatography, and the results are shown in Table 1.

The measuring method comprises the following steps:

(1) Chromatographic conditions: kromasil C18 column (4.6 mm. Times.250 mm,5 μm). Mobile phase a was 0.1% (volume fraction) aqueous formic acid and B was methanol. The gradient elution procedure was: 0-30min,70% A-60A;30-35min,60% A-70A;35-40min,70% A-60A;0-30min,70% A-60A. The detection wavelength is 330nm, the flow rate is 1mL/min, the temperature of a column temperature box is 30 ℃, and the sample injection volume is 10 mu L. The contents of echinacoside and acteoside were measured separately.

(2) Preparation of standard solution: taking proper amount of echinacoside and acteoside standard substance, precisely weighing, adding 50% (volume fraction) methanol to obtain mixed solution containing echinacoside and acteoside, wherein the contents of echinacoside and acteoside are respectively 0.2mg/mL.

(3) Establishment of a standard curve: precisely sucking 0.2mL, 0.5mL, 1mL, 1.5mL and 2mL of standard substance solution, respectively placing into 10mL measuring flask, fixing volume with 50% methanol (volume fraction), and shaking. And (3) injecting the standard substance solutions with different concentrations into a liquid chromatograph, recording a chromatogram with the sample injection amount of 10 mu L, drawing a standard curve with the peak area as an ordinate and the standard substance concentration as an abscissa, and performing linear regression.

(4) Preparation of the solution of the sample: the cistanche extracts in examples 1-4 and comparative examples 1-3 were respectively ground into about 0.5g of powder (sieved by a fourth sieve), precisely weighed, placed in a 50mL volumetric flask, precisely added with 25mL of 50% methanol (volume fraction), sealed, wrapped with a sealing film, weighed by weight, soaked for 30min, placed in ultrasound for 40min (power 250W, frequency 35 kHz), weighed after cooling, complemented with weight loss, sucked by a syringe, then injected into a 0.22 mu m filter membrane, placed in a liquid phase flask, and subjected to content measurement.

TABLE 1

From table 1, the following points can be seen:

(1) as can be seen from the data of examples 1-4, the extraction rate of phenylethanoid glycosides in cistanche deserticola extract is more than or equal to 11.4mg/g of cistanche deserticola, and compared with the extraction rate of phenylethanoid glycosides in cistanche deserticola raw material being 10.3mg/g of cistanche deserticola, examples 1-4 can significantly improve the extraction rate of phenylethanoid glycosides.

(2) As can be seen from the data of the example 2 and the comparative example 1, the cistanche extract is prepared by adopting the ethanol extraction method in the comparative example 1, the extraction rate of phenylethanoid glycosides in the cistanche extract obtained in the example 2 is 18.9mg/g of cistanche as a raw material, and the extraction rate of phenylethanoid glycosides in the cistanche extract obtained in the comparative example 1 is only 7.5mg/g of cistanche as a raw material, so that the preparation method of the cistanche extract provided by the invention can effectively improve the extraction rate of phenylethanoid glycosides.

(3) As can be seen from the data of example 2 and comparative examples 2-3, comparative example 2 differs from example 2 only in that step (1) is omitted, comparative example 3 differs from example 2 only in that step (2) is not added with beta-cyclodextrin, the extraction rate of phenylethanoid glycosides in cistanche extract obtained in example 2 is 18.9mg/g raw material cistanche, whereas comparative example 2 is only 8.6mg/g raw material cistanche, and comparative example 3 is only 13.3mg/g raw material cistanche, thereby indicating that the preparation method of cistanche extract provided by the present invention can effectively provide the extraction rate of phenylethanoid glycosides by acid liquor treatment, and combined operations of solvent and cyclodextrin extraction, etc.

In conclusion, the preparation method of the cistanche deserticola extract provided by the invention can obviously improve the content of phenylethanoid glycosides in the cistanche deserticola extract, improve the solubility of phenylethanoid glycosides, and ensure that the extraction rate of phenylethanoid glycosides is more than or equal to 11.4mg/g of cistanche deserticola raw material.

Application example 1

The application example provides an anti-hangover and liver-protecting product, which comprises 20 parts of cistanche extract, 6 parts of pueraria extract, 4 parts of licorice extract, 5 parts of hovenia dulcis thunb extract, 2 parts of poria cocos extract, 4 parts of medlar extract, 3 parts of astragalus extract, 2 parts of schisandra chinensis extract and 10 parts of cranberry extract in parts by weight; the cistanche extract was prepared in example 1.

The preparation method of the anti-hangover and liver-protecting product comprises the following steps: mixing above herba cistanches extract, radix Puerariae extract, radix Glycyrrhizae extract, semen Hoveniae extract, poria extract, fructus Lycii extract, radix astragali extract, fructus Schisandrae chinensis extract, vc, xylitol and cranberry extract, and sequentially preparing into tablet by compounding, pressing into pill, shaping, drying, inspecting pill, packaging, inspecting and packaging.

Application example 2

The application example provides an anti-hangover and liver-protecting product, which comprises, by weight, 10 parts of cistanche extract, 2 parts of pueraria extract, 1 part of licorice extract, 2 parts of hovenia dulcis thunb extract, 1 part of poria cocos extract, 1 part of medlar extract, 1 part of astragalus extract, 1 part of schisandra chinensis extract, 0.2 part of Vc, 0.2 part of xylitol and 3 parts of cranberry extract; the cistanche extract was prepared in example 2.

The preparation method of the anti-hangover and liver-protecting product comprises the following steps: mixing above herba cistanches extract, radix Puerariae extract, radix Glycyrrhizae extract, semen Hoveniae extract, poria extract, fructus Lycii extract, radix astragali extract, fructus Schisandrae chinensis extract and cranberry extract, and sequentially preparing into capsule, pressing into pill, shaping, drying, inspecting pill, packaging, inspecting and packaging.

Application example 3

The application example provides an anti-hangover and liver-protecting product, which comprises, by weight, 1 part of cistanche extract, 2 parts of pueraria extract, 1 part of licorice extract, 2 parts of hovenia dulcis thunb extract, 1 part of poria cocos extract, 1 part of wolfberry extract, 10 parts of astragalus extract, 5 parts of schisandra chinensis extract and 1 part of cranberry extract; the cistanche extract was prepared in example 3.

The preparation method of the anti-hangover and liver-protecting product comprises the following steps: mixing the above herba cistanches extract, radix Puerariae extract, radix Glycyrrhizae extract, semen Hoveniae extract, poria extract, fructus Lycii extract, radix astragali extract, fructus Schisandrae chinensis extract and cranberry extract, and sequentially mixing, shaping, drying, testing, packaging, inspecting, and packaging to obtain solid beverage.

Application example 4

The application example provides an anti-hangover and liver-protecting product, which comprises, by weight, 25 parts of cistanche extract, 4 parts of pueraria extract, 3 parts of licorice extract, 8 parts of hovenia dulcis thunb extract, 5 parts of poria cocos extract, 5 parts of medlar extract, 1 part of astragalus extract, 1 part of schisandra chinensis extract and 5 parts of cranberry extract; the cistanche extract was prepared in example 4.

Application example 5

The application example provides an anti-hangover and liver-protecting product, which comprises 15 parts of cistanche extract, 10 parts of pueraria extract, 10 parts of licorice extract, 10 parts of hovenia dulcis thunb extract, 10 parts of poria cocos extract, 10 parts of medlar extract, 5 parts of astragalus extract, 10 parts of schisandra chinensis extract and 5 parts of cranberry extract in parts by weight; the cistanche extract was prepared in example 1.

The preparation method of the anti-hangover and liver-protecting product comprises the following steps: mixing above herba cistanches extract, radix Puerariae extract, radix Glycyrrhizae extract, semen Hoveniae extract, poria extract, fructus Lycii extract, radix astragali extract, fructus Schisandrae chinensis extract and cranberry extract, and sequentially mixing, packaging, inspecting and packaging to obtain oral liquid.

Comparative example 1 was used

The application comparative example provides an anti-hangover and liver-protecting product, which comprises 20 parts of maca extract, 6 parts of radix puerariae extract, 5 parts of turmeric extract, 5 parts of hovenia dulcis thunb extract, 4 parts of licorice extract, 2 parts of poria extract, 4 parts of wolfberry extract and 10 parts of cranberry extract in parts by weight.

The preparation method of the anti-hangover and liver-protecting product in the application comparative example comprises the following steps: mixing the above Lepidium meyenii extract, radix Puerariae extract, curcuma rhizome extract, semen Hoveniae extract, glycyrrhrizae radix extract, poria extract and fructus Lycii extract, and sequentially mixing, pressing into pill, shaping, drying, checking pill, packaging, checking and packaging to obtain tablet.

1. Application test: taking application example 1 and application comparative example 1 as examples, the anti-drunk, anti-drunk and post-drunk climbing experiments are carried out on ICR mice by using the anti-drunk and post-drunk liver protection products prepared in application example 1 and application comparative example 1, and the influence of the anti-drunk liver protection products on the post-drunk behaviors of the mice is examined.

Experimental materials: ICR mice, male and female halves, weight about 25g, were bred in SPF-class animal houses; a gastric lavage device; a timer; application example 1 an anti-hangover and liver-protecting product; the anti-hangover and liver-protecting product of comparative example 1 was used; RU-21 anti-hangover agent (RU-21 as positive control); 42 DEG ox fence mountain Erguotou; child haha purified water.

Experimental grouping: the ICR mice are 96, male and female half, and the weight is about 25g, and the ICR mice are randomly divided into a blank control group, a positive control group, an application example 1 low dose group, an application example 1 medium dose group, an application example 1 high dose group, an application comparative example 1 low dose group, an application comparative example 1 medium dose group and an application comparative example 1 high dose group, 8 groups are total, and 12 ICR mice are used in each group; the low dose, the medium dose and the high dose are respectively 10 times, 20 times and 40 times of the recommended intake of the human body, namely 200mg/kg, 400mg/kg and 800mg/kg.

The experimental method comprises the following steps:

(1) Anti-drunk experiment of mice

96 ICR mice were treated differently according to the group, and after 12 hours of fasted before the experiment, the blank control group, the positive control group, the application example 1 low dose group, the application example 1 medium dose group, the application example 1 high dose group, the application comparative example 1 low dose group, the application comparative example 1 medium dose group, the application comparative example 1 high dose group were respectively perfused with 2mL/kg of baby haha purified water, 200mg/kg RU-21, 200mg/kg application example 1 anti-alcoholic liver-protecting product, 400mg/mL application example 1 anti-alcoholic liver-protecting product, 800mg/kg application example 1 anti-alcoholic liver-protecting product, 200mg/kg application comparative example 1 anti-alcoholic liver-protecting product, 400mg/mL application comparative example 1 anti-alcoholic liver-protecting product and 800mg/kg application comparative example 1 anti-alcoholic liver-protecting product. After 30min of gastric lavage, each group of mice was lavaged with a 1mL/kg dose of 42 ° niuzhushan er guotou, immediately starting timing, and the behavior of the mice was recorded, and the drunk (disappearance of the anti-positive reflex) and the sober-up time (recovery of the anti-positive reflex) of each mouse were determined.

(2) Mouse anti-alcohol experiment

96 ICR mice are treated according to grouping distinction, after 12 hours of fasted period before experiment, each group of mice is infused with 1mL/kg of 42 DEG cattle and mountain Erguotor with a dose, after 30 minutes, a blank control group, a positive control group, a low dose group of application example 1, a high dose group of application example 1, a low dose group of application comparative example 1, a high dose group of application comparative example 1, 2mL/kg of baby haha purified water respectively infused with the dose group of application comparative example 1, 200mg/kg RU-21, 200mg/kg of application example 1 anti-alcoholic liver protection product, 400mg/mL of application example 1 anti-alcoholic liver protection product, 800mg/kg of application example 1 anti-alcoholic liver protection product, 200mg/kg of application comparative example 1 anti-alcoholic liver protection product, and 800mg/kg of application comparative example 1 are used, and immediately starting timing is recorded, and the anti-alcoholic time (anti-reflection recovery) of the mice is determined.

(3) Mouse climbing experiment after drinking

96 ICR mice were treated differently according to the grouping method, and after 12 hours of fasted prior to the experiment, the blank control group, the positive control group, the application example 1 low dose group, the application example 1 medium dose group, the application example 1 high dose group, the application comparative example 1 low dose group, the application comparative example 1 medium dose group, the application comparative example 1 high dose group were respectively perfused with 2mL/kg of baby haha purified water, 200mg/kg RU-21, 200mg/kg of application example 1 anti-alcoholic liver-protecting product, 400mg/mL of application example 1 anti-alcoholic liver-protecting product, 800mg/kg of application example 1 anti-alcoholic liver-protecting product, 200mg/kg of application comparative example 1 anti-alcoholic liver-protecting product, 400mg/mL of application comparative example 1 anti-alcoholic liver-protecting product and 800mg/kg of application comparative example 1 anti-alcoholic liver-protecting product were used. After 30min of gastric lavage, each group of mice was lavaged with a 1mL/kg dose of 42 ° niuzhushan er guotou, and then immediately placed on a vertical metal mesh, the activity of the mice was observed, and the time of climbing of each group of mice was recorded at the same time.

Experimental results:

(1) Anti-drunk experiment of mice

The results of application example 1 and application comparative example 1, as measured by the number of drunk mice, the number of falling asleep, the sobering-up time and the significance level in the anti-drunk mice experiments, are shown in table 2 and fig. 1.

TABLE 2

In table 2, "a", "b", "c", "d", "e", "ab" and "cd" represent the significance classes of the different data, the data containing the same letters are considered not significant in difference, and the data not containing the same letters are considered significant in difference, e.g., c is significant in difference from b, and b is not significant in difference from ab.

From table 2, the following points can be seen:

(1) compared with a blank control group, the low-dose group in application example 1, the high-dose group in application example 1 and the high-dose group in application example 1 obviously shorten the sobering-up time, so that the anti-hangover and liver-protecting product provided by the invention has a better anti-drunk effect compared with the blank control group.

(2) The low dose group of application example 1, the dose group of application example 1 and the high dose group of application example 1 have the advantages that although the sobering time is slightly higher than that of a positive control group, the sobering time is obviously lower than that of a blank control group, and RU-21 used in the positive control group has the defects of high price, large side effect and the like, so that the anti-hangover and liver-protecting product provided by the invention has better anti-hangover effect, can improve human immunity, protect liver and avoid side effect after being taken for a long time.

(3) The low dose group of application example 1, the dose group of application example 1 and the high dose group of application example 1 are compared, the dose group of application example 1 and the low dose group of application example 1 have significant differences, but the high dose group of application example 1 does not have significant differences relative to the dose group of application example 1, so that the anti-hangover and liver-protecting product provided by the invention has better anti-drunk effects under medium dose and high dose.

(4) The results of the comparison of the low dose group of application example 1, the high dose group of application example 1 and the low dose group of application comparative example 1, the dose group of application comparative example 1 and the high dose group of application comparative example 1 show that the anti-hangover liver-protecting product of application example 1 obviously shortens the anti-hangover time and the anti-hangover effect is obviously better than that of application comparative example 1, thus showing that the anti-hangover liver-protecting product provided by the invention has better anti-hangover effect.

(2) Mouse anti-alcohol experiment

The results of application example 1 and application comparative example 1, as measured by the number of drunk mice, the number of falling asleep, the sobering-up time and the significance level in the anti-hangover test of mice, are shown in table 3 and fig. 2.

TABLE 3 Table 3

In table 3, "a", "b", "c", "d", "e", "f", "bc" and "cd" represent the significance levels of the different data, the data containing the same letters are regarded as not significant, and the data not containing the same letters are regarded as significant, for example: a is significantly different from b, and b is not significantly different from bc.

From Table 3, the following points can be seen:

(1) compared with a blank control group, the low-dose group in application example 1, the high-dose group in application example 1 and the high-dose group in application example 1 obviously shorten the sobering-up time, so that the sobering-up liver-protecting product provided by the invention has a better sobering-up effect compared with the blank control group.

(2) The low dose group of application example 1, the dose group of application example 1 and the high dose group of application example 1 have the advantages that although the sobering time is slightly higher than that of a positive control group, the sobering time is obviously lower than that of a blank control group, and RU-21 used in the positive control group has the defects of high price, large side effect and the like, so that the product for dispelling the effects of alcohol and protecting the liver has good anti-alcohol effect, can improve the immunity of a human body, protects the liver and can be taken for a long time, and side effects are avoided.

(3) The low dose group of application example 1, the dose group of application example 1 and the high dose group of application example 1 are compared, and the high dose group of application example 1 and the low dose group of application example 1 have significant differences, so that the anti-hangover and liver-protecting product provided by the invention has better anti-hangover effect when being used at high dose compared with low dose.

(3) Mouse climbing experiment after drinking

The results of application example 1 and comparative example 1 were shown in table 4 and fig. 3 by measuring the number of mice not dropped, the time of climbing and the significance level in the mouse post-drunk climbing experiment.

TABLE 4 Table 4

In table 4, "a", "b", "c", "d" and "e" represent the significance level of the different data, the data containing the same letter is considered not significant in difference, and the data not containing the same letter is considered significant in difference, e.g., a is significant in difference compared to b, and e is not significant in difference compared to e.

From Table 4, the following points can be seen:

(1) compared with a blank control group, the low dose group of application example 1, the dose group of application example 1 and the high dose group of application example 1 can improve the climbing time of mice, so that the anti-hangover and liver-protecting product provided by the invention has the effect of regulating the behavior after drinking.

(2) Although the climbing time of the low-dose group of application example 1 is lower than that of the positive control group, the dose group of application example 1 and the high-dose group of application example 1 are higher than those of the positive control group, and RU-21 used in the positive control group has the defects of high price, large side effect and the like, so that the anti-hangover liver-protecting product provided by the invention has better effect of regulating and controlling the behavior after drinking, can improve the immunity of a human body, protect the liver and avoid side effect after long-term administration.

(3) The low dose group of application example 1, the dose group of application example 1 and the high dose group of application example 1 are compared, the high dose group of application example 1 has significant differences relative to the low dose group of application example 1, and the dose group of application example 1 and the high dose group of application example 1 have no significant differences, so that the effect of regulating and controlling the drunk behavior of the anti-hangover liver-protecting product provided by the invention is more significant under the medium dose and the high dose.

(4) The comparison of the low dose group of application example 1, the high dose group of application example 1, the low dose group of application example 1 and the low dose group of application comparative example 1, the application of the dose group of comparative example 1 and the high dose group of application comparative example 1 shows that the anti-hangover liver-protecting product of application example 1 obviously improves the climbing time and the effect of regulating the post-hangover behaviour is obviously better than that of application comparative example 1, thereby showing that the anti-hangover liver-protecting product provided by the invention has better effect of regulating the post-hangover behaviour.

The anti-drunk experiment, the anti-drunk experiment and the drunk climbing experiment show that the anti-drunk liver-protecting product provided by the invention has better effects of preventing drunk, dispelling alcohol and regulating drunk behaviors, can promote alcohol to be rapidly absorbed and decomposed in vivo, and shortens the anti-drunk time.

2. Test feeding experiment: taking application example 1 and application comparative example 1 as examples, the anti-hangover and liver-protecting products prepared in application example 1 and application comparative example 1 were subjected to a test feeding experiment on human bodies, 400 drinkers were randomly divided into a placebo group, a positive control group (RU-21 is used as a positive control), application example 1 groups and application comparative example 1 groups, 4 groups are taken respectively by 100 persons in each group, 1g of placebo, 1g of RU-21,1g of anti-hangover and liver-protecting products in application example 1,1g of anti-hangover and liver-protecting products in application comparative example 1, the other conditions of each group of experiments were kept the same, and the number of cases with anti-hangover effects was observed and recorded, and the results are shown in Table 5. Wherein the main component of placebo is starch.

TABLE 5

	Placebo	Positive control group	Application example 1	Comparative example 1 was used
					Has the following characteristics ofNumber of cases with anti-hangover effect	2	82	93	87

As can be seen from Table 5, the number of cases of alcohol disintoxication in application example 1 is obviously higher than that of a placebo group, a positive control group and an application comparison example 1, so that the alcohol disintoxication liver-protecting product provided by the invention can promote the rapid absorption and decomposition of alcohol in vivo, is beneficial to the rapid alcohol disintoxication of alcohol ingestion people, prevents hangover, and can be added into food in proper amount to obtain functional food so as to play a role in protecting liver.

In conclusion, the preparation method of the cistanche deserticola extract provided by the invention can obviously improve the content and the extraction rate of phenylethanoid glycosides in the cistanche deserticola extract, and the extraction rate of phenylethanoid glycosides is more than or equal to 11.4mg/g of cistanche deserticola raw material. The anti-hangover and liver-protecting product provided by the invention can promote the rapid absorption and decomposition of alcohol in vivo, has good effects on rapidly relieving alcohol and preventing hangover for alcohol ingestion, has good liver-protecting effect, increases the metabolism speed of alcohol in vivo, effectively relieves symptoms such as headache, dizziness, nausea, vomiting, fever, polydipsia and the like after drunk, shortens the anti-hangover time, and has good effect on preventing liver injury caused by alcohol metabolism.

The applicant declares that the above is only a specific embodiment of the present invention, but the scope of the present invention is not limited thereto, and it should be apparent to those skilled in the art that any changes or substitutions that are easily conceivable within the technical scope of the present invention disclosed by the present invention fall within the scope of the present invention and the disclosure.

Claims

1. A preparation method of cistanche extract, which is characterized by comprising the following steps:

(1) Mixing cistanche deserticola and acid liquor to obtain pretreated cistanche deserticola; the mixing comprises soaking for 0.25-24h, wherein the soaking temperature is 5-100 ℃, and the mass percentage of the acid liquor is 0.01-5%;

(2) Mixing the pretreated cistanche salsa, the ethanol solution and the cyclodextrin auxiliary agent obtained in the step (1), extracting after mixing, and then carrying out solid-liquid separation to obtain an extracting solution;

the cyclodextrin auxiliary agent comprises any one or a combination of at least two of alpha-cyclodextrin, beta-cyclodextrin, gamma-cyclodextrin or hydroxypropyl-beta-cyclodextrin;

2. The method of claim 1, wherein the acid solution in step (1) comprises any one or a combination of at least two of citric acid, ascorbic acid, hydrochloric acid, phytic acid, L-cysteine, potassium sorbate, sulfuric acid, phosphoric acid, oxalic acid, and glycine.

3. The method according to claim 1, wherein the cistanche salsa in step (1) comprises cistanche deserticola and/or cistanche tubulosa.

4. A method according to claim 3, wherein the cistanche salsa in step (1) is cistanche deserticola.

5. The method according to claim 1, wherein the cistanche salsa in step (1) comprises fresh cistanche salsa and/or dry cistanche salsa.

6. The method according to claim 5, wherein the cistanche salsa in step (1) is fresh cistanche salsa.

7. The method according to claim 1, wherein the cistanche salsa in step (1) is sliced before being mixed.

8. The method of claim 7, wherein the thickness of the slice in step (1) is 1-10mm.

9. The method according to claim 1, wherein the volume concentration of ethanol after mixing in step (2) is 20 to 80%.

10. The preparation method according to claim 1, wherein the solid-to-liquid ratio of the pretreated cistanche salsa to the ethanol solution in the step (2) is 1 (10-50) g/L.

11. The preparation method according to claim 1, wherein the mass of the cyclodextrin auxiliary agent in the step (2) is 10-80% of the solid content of the pretreated cistanche deserticola.

12. The process according to claim 1, wherein the extraction temperature in step (2) is 50-80 ℃.

13. The method of claim 1, wherein the extraction time in step (2) is 0.25 to 4 hours.

14. The method of claim 1, wherein the concentrating of step (3) comprises vacuum concentrating under reduced pressure.

15. The method of claim 1, wherein the concentration in step (3) is at a temperature of 60-80 ℃.

16. The method according to claim 1, wherein the concentration in step (3) is terminated at a specific gravity of the extract of 1.1 to 1.15.

17. The method of claim 1, wherein the drying of step (3) comprises spray drying.